Lisa J Wood, Ph.D., R.N.
- Email:
- click here
- Phone:
- 503 494-3431
Summary of Current Research
The long-range goal of our research is to effectively treat and manage the most common symptom experienced by cancer patients undergoing chemotherapy, radiation therapy or both; fatigue. To date the molecular mechanisms underlying the initiation and perpetuation of CTRF are not well established, and, the precise role of inflammatory cytokines, if any, in CTRF remains unclear. Our research program utilizes a pre-clinical and clinical approach to examine the relationship between cancer treatment, inflammatory cytokines and CTRF. This “bench to bedside” approach to understanding the cause of CTRF arises from a unique interdisciplinary collaboration among molecular, behavioral, and clinical investigators all working at various points within the spectrum of cancer research at our institution and hence, represents a major innovation in cancer symptom research.
Selected Publications
"Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin,"
"Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome,"
"An epidermotypic model of interface dermatitis reveals individual functions of fas ligand and gamma interferon in hypergranulosis, cytoid body formation, and gene expression,"
"A specific need for CRKL in p210BCR-ABL - Induced transformation of mouse hematopoietic progenitors,"
"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms,"
